Hormone Replacement Therapy in Women Over 80

Primary Guideline Recommendations

The American College of Physicians explicitly contraindicates initiating HRT in women over 65 for chronic disease prevention, as it increases morbidity and mortality, and recommends reassessing necessity and attempting discontinuation for women already on HRT at age 65, using the absolute lowest effective dose if continuation is deemed essential 1
The U.S. Preventive Services Task Force recommends against routine use of estrogen and progestin for prevention of chronic conditions in postmenopausal women, noting that harmful effects likely exceed chronic disease prevention benefits, particularly in women many years past menopause, with a Grade D recommendation 1
The risk-benefit profile of HRT is most favorable for women ≤60 years old or within 10 years of menopause onset, but in women ≥60 years of age or more than 10 years after natural menopause, oral estrogen-containing HRT is associated with excess risk of stroke 1

For genitourinary symptoms only, low-dose vaginal estrogen is preferred over systemic therapy, with minimal systemic absorption and 60-80% improvement in symptom severity, according to the Journal of Clinical Oncology 2, 1
For vasomotor symptoms, consider non-hormonal alternatives including paroxetine, venlafaxine, gabapentin, or clonidine, though paroxetine should not be used with tamoxifen, as recommended by the Journal of Clinical Oncology 2
Vaginal moisturizers and lubricants can reduce symptom severity by up to 50%, as reported by the Journal of Clinical Oncology and Praxis Medical Insights 2, 1

Cardiovascular risks include 7 additional CHD events, 8 more strokes, and 8 more pulmonary emboli per 10,000 women taking estrogen-progestin for 1 year, according to Praxis Medical Insights 1
Breast cancer risk is increased, with 8 additional invasive breast cancers per 10,000 women-years with combined estrogen-progestin therapy, as reported by Praxis Medical Insights 1
Stroke risk is particularly elevated in women ≥60 years or more than 10 years past menopause with oral estrogen formulations, according to Praxis Medical Insights 1

Absolute contraindications at any age include history of breast cancer, coronary heart disease, previous venous thromboembolic event or stroke, active liver disease, and antiphospholipid syndrome, as stated by Praxis Medical Insights 1
Do not continue HRT solely for osteoporosis prevention at age 80, as alternative therapies have superior risk-benefit profiles for this indication, according to Praxis Medical Insights 1

The Women's Health Initiative demonstrated that combined estrogen and progestin therapy showed a trend toward increased risk for coronary heart disease (CHD) after 5 years (HR 1.22; 95% CI 0.99-1.50), and stroke risk was significantly elevated (HR 1.36; 95% CI 1.08-1.71) in postmenopausal women, according to the U.S. Preventive Services Task Force 3
The risk of coronary heart disease is increased with estrogen-progestin therapy, with a hazard ratio of 1.22 (95% CI 0.99-1.50) after 5 years of treatment, as reported by the Women's Health Initiative 3

Breast cancer risk increases with 8 additional invasive breast cancers per 10,000 women-years with combined estrogen-progestin therapy, with a hazard ratio of 1.25 (95% CI 1.07-1.46), according to the Women's Health Initiative 3

Estrogen plus progestin significantly increases the risk of probable dementia (HR 2.05; 95% CI 1.21-3.48) in women aged 65-79 years, as demonstrated by the WHI Memory Study 3
Both combined therapy and estrogen alone are associated with increased risk of a composite outcome of probable dementia or mild cognitive impairment, according to the WHI Memory Study 3

The American College of Physicians and other guideline societies recommend against initiating oral estrogen therapy in women with a history of coronary heart disease, due to the increased risk of adverse cardiovascular events 3